Itonis, Inc. Provides Update for its Emesyl® Anti-nausea Product Sales

Laguna Hills, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- 

LAGUNA HILLS, CA – (January 2, 2018) - Itonis, Inc. (OTC PINKSHEETS: ITNS) is pleased to provide this update on its Emesyl® anti-nausea homeopathic product’s ongoing sales.

Emesyl® continues to be listed for sale in Amazon’s Health, Household & Personal Care category:  We are extremely proud that Emesyl® has attained “Amazon’s Choice” status.

We have also made recent sales to distribution/reseller firms for their placement of Emesyl® for retail re-sale via online and/or brick-and-mortar store outlets.  Those sales were not on consignment nor conditional, hence, the firms will handle their resell efforts of their respective Emesyl® inventory.

In support of the sales effort, we have also produced a new animation video for Emesyl® that is available at our Facebook page:

Meanwhile, Emesyl® enjoys very positive reviews posted by “verified purchasers” at 

“I have Crohns Disease and tend to have bouts of nausea.    …  “I have used this several times now and it definitely provides relief and allows me to settle down (my nausea and vomiting usually wakes me up during the night) and go to sleep.  (Justin, Nov 2017)

“I ordered this product in anticipation of a trip to Disneyland and Universal Studios CA.   …   Unfortunately when the bottle arrived, it had been crushed in shipping …     Itonis responded immediately and rush shipped me a new bottle in time for my trip two days later. They emailed to check on it’s arrival and were so helpful!  …  I am so grateful to not spend the day nauseated. I completely recommend this product and company, THANKS!”   (Michelle, Nov 2017)

“This product enabled me to have an enjoyable time on my trip. As soon as I returned home I ordered another bottle.”  (Robyn, Oct 2017)

“I bought this product for the plane ride.   …    I use one squirt in each nostril before the plane take off and I haven't gotten sick yet!  [I]t has definitely worked for me.”  (Kurt, Oct 2017) 

“It really worked on my seasick nausea.”  (Gogie888, Oct 2017)

“Great product works quickly.”  (Sam, July 2017)

 “We’re very pleased that Emesyl® is enjoying increasing sales on Amazon.  But, more importantly, it is heartening to see the customer reviews that confirm our knowledge that Emesyl® truly works as a superior product to provide relief to people who suffer from nausea.  Our management team is so happy to have provided an improved-quality-of-life change to our customers, says Mark Cheung, Itonis’ CEO.  “Meanwhile, please know that Dr. Charles Hensley has been continuing with his research and development on our line of products, so please stay tuned.  Hopefully, we will have more news to share in the coming months on that score.  We continue to strive to make Emesyl® a household brand name with distribution in big box retailers.  We wish all our shareholders and supporters a Happy New Year and a healthy and prosperous 2018!”   

About Itonis, Inc.

Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company is actively selling its Emesyl® nausea relief product on and our own websites.  Please visit for additional information.   

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


Contact Data